Intervention
Rifaximin
ClinicalTrials.gov intervention label
Clinical trials
14 shownRifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection FractionNCT06652087 · 2024-09-02
RECRUITINGRifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast CancerNCT04249622 · 2020-09-18
TERMINATEDMicrobiota Intervention to Change the Response of Parkinson's DiseaseNCT03575195 · 2019-07-15
SUSPENDEDRifaximin in Patients With Gastroesophageal Variceal BleedingNCT02991612 · 2016-11-25
COMPLETEDEfficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal BleedingNCT02964195 · 2016-11-01
UNKNOWNGutHeart: Targeting Gut Microbiota to Treat Heart FailureNCT02637167 · 2016-03-11
UNKNOWNTreating Bacterial Overgrowth in Parkinson's DiseaseNCT02470780 · 2015-12-01
COMPLETEDEffect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal VaricesNCT02508623 · 2015-07-01
UNKNOWNQuality of Life and Nutritional Improvements in Cirrhotic PatientsNCT01842113 · 2013-04-01
TERMINATEDRifaximin for Chronic Immune Activation in People With HIVNCT01866826 · 2013-01-18
COMPLETEDImpact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver DiseaseNCT01654939 · 2012-10-01
WITHDRAWNWeight Loss in Parkinson's Disease and Role of Small Bowel Bacterial OvergrowthNCT01662791 · 2012-09-01
COMPLETEDRole of Methane in Glycemic ControlNCT01638429 · 2012-04-01
COMPLETEDRifaximin as a Modulator of Microbial Translocation and Immune ActivationNCT01466595 · 2011-09-01
COMPLETEDCommon conditions
Cirrhosis2Esophageal and Gastric Varices2Gastrointestinal Hemorrhage2HIV2Liver Cirrhosis2Parkinson's Disease2Portal Hypertension2Anatomic Stage I Breast Cancer AJCC v81Anatomic Stage IA Breast Cancer AJCC v81Anatomic Stage IB Breast Cancer AJCC v81Anatomic Stage II Breast Cancer AJCC v81Anatomic Stage IIA Breast Cancer AJCC v81Anatomic Stage IIB Breast Cancer AJCC v81Anatomic Stage III Breast Cancer AJCC v81Anatomic Stage IIIA Breast Cancer AJCC v81Anatomic Stage IIIB Breast Cancer AJCC v81Anatomic Stage IIIC Breast Cancer AJCC v81Bacterial Overgrowth Syndrome Small Bowel1Diabetes1Heart Failure with Preserved Ejection Fraction1Hepatic Encephalopathy1Hepatitis C1HER2 Positive Breast Carcinoma1HIV-1 Infection1Obesity1
Leading sponsors
Mayo Clinic2Shanghai Zhongshan Hospital2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections1Cedars-Sinai Medical Center1Douglas T. Dieterich1I.M. Sechenov First Moscow State Medical University1National Cancer Institute (NCI)1Oslo University Hospital1Tampa General Hospital1University of California, San Francisco1University of Cincinnati1University of Padova1
Trial status mix
COMPLETED6
UNKNOWN3
TERMINATED2
RECRUITING1
SUSPENDED1
WITHDRAWN1
Phase mix
PHASE26
NA3
PHASE33
PHASE12
PHASE42
EARLY_PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.